Darzalex from Genmab A/ S - subcutaneous dosing reshapes myeloma care
28.06.2026 - 05:11:12 | ad-hoc-news.de
Reviewed: ad hoc news Classics & Longseller desk. Edited and checked on 2026-06-28, 05:08. Details in the imprint.
Darzalex is the name that many hematology patients now associate with long mornings in infusion chairs and, more recently, a quicker subcutaneous jab that feels closer to a routine clinic visit than a full hospital day. You see the small clear vial or prefilled syringe, the nurses know the drill, and the whole room breathes a little easier when the drip time shrinks.
How Darzalex works
Darzalex, generically daratumumab, is a monoclonal antibody that targets CD38 on multiple myeloma cells, helping the immune system mark and clear them. In practice, that means it is added to standard backbones like bortezomib or lenalidomide to deepen response rates and extend remission.
In trial data, combinations with Darzalex have shown higher rates of complete response and longer progression-free survival than the same regimens without the antibody, which is why oncologists increasingly reach for it early in the treatment journey.
From infusion to subcutaneous
One of the biggest shifts around Darzalex is the move from lengthy intravenous infusions to a subcutaneous formulation given as an injection over minutes rather than hours. For patients, the difference is palpable: less time in a recliner under fluorescent lights, more time at home or back at work.
Clinicians describe the first IV dose as a half-day commitment, especially in elderly patients needing close monitoring, while the subcutaneous form compresses this into a tighter, more predictable slot without the same level of chair fatigue.
Background on Genmab A/S shares
Darzalex is one of the key antibody assets that shapes how investors view Genmab A/S and its long-term royalty stream from hematology.
What patients actually feel
Ask a patient like Maria, a 63-year-old retired teacher on Darzalex, and you hear about the small rituals of therapy days: the chill of saline as the IV starts, the faint antiseptic smell, the click of the pump, and the relief when the nurse says, “Only twenty minutes left.”
On subcutaneous days, Maria describes a sharper, brief sting at the injection site and then a quiet watchful period for reactions, but the physical and mental load feels lighter compared with being tethered to a slow drip.
Safety and premedication
Because Darzalex can trigger infusion-related reactions, especially with the first dose, protocols include premedication with steroids, antihistamines and antipyretics, plus observation time before patients are allowed to leave. Nurses are trained to watch for cough, chills or drop in blood pressure.
The subcutaneous route has been associated with a lower rate of severe infusion-related events versus IV, yet the routine safety measures remain, which adds to the perceived robustness of the regimen among hospital pharmacists and ward staff.
Position in myeloma therapy lines
Darzalex now appears across multiple lines of myeloma therapy: newly diagnosed transplant-eligible, transplant-ineligible and relapsed settings. It joins proteasome inhibitors and immunomodulatory drugs, creating triplet or quadruplet combinations that reflect a more aggressive, layered approach to the disease.
For a treating physician, this means carefully sequencing Darzalex with other agents to maintain options down the line, while still hitting the cancer hard enough early on to achieve a convincing depth of response.
Genmab and Janssen partnership
Genmab developed daratumumab and licensed it to Janssen, which handles global commercialization and distribution, especially in the United States and Europe. Royalties from Darzalex and milestone payments form a significant part of Genmab’s revenue stream.
Genmab CEO Jan van de Winkel often points to Darzalex as proof of the company’s antibody engineering platform, arguing that the drug’s success validates both the science and the partnering model with big pharma.
Home-market availability and pricing
In Denmark, where Genmab is headquartered, Darzalex is available through hospital-based oncology centers under national reimbursement frameworks, typically as part of combination regimens rather than standalone therapy. Pricing follows negotiated agreements at the health-system level.
For individual patients, the visibility is less about list price and more about whether the treatment is covered for their specific disease stage, which health authorities regularly reassess based on new trial data.
How the product shapes the stock
Darzalex has turned into a classic long-running franchise in multiple myeloma, anchoring perceptions of Genmab as a company with durable royalty streams rather than purely early-stage biotech risk. This feeds into how analysts model cash flows and pipeline leverage.
On Nasdaq Copenhagen, Genmab shares (ISIN DK0010272202) trade as a large-cap biotech name, and Darzalex remains one of the central products investors watch when updating scenarios for revenue growth and margin stability.
Key facts on Darzalex
- Product: Darzalex (daratumumab)
- Manufacturer: Genmab A/S
- Category: Classic longseller oncology biologic
- Launch: Initial IV approval in the mid-2010s, subcutaneous formulation approved later for broader use
- RRP / Price: Hospital-only biologic pricing, subject to national reimbursement agreements rather than retail RRP
- Availability: Prescription-only via oncology and hematology centers, including Denmark, Europe and the United States
- Target group: Adults with multiple myeloma in newly diagnosed and relapsed settings, in combination with standard therapies
- Highlight / USP: CD38-targeting antibody with established efficacy and a subcutaneous option that cuts chair time
This article was AI-assisted and editorially reviewed. Product information without guarantee; prices and availability may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions involve risks up to total loss.
